The interferon regulatory factor 6 promotes cisplatin sensitivity in colorectal cancer

References

• Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–117.
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal cancer. Nat Rev Dis Primers. 2015;1:15065.
   PubMed Web of Science ®Google Scholar
• Tuerxun W, Wang Y, Cui C, et al. Expression pattern of the interferon regulatory factor family members in influenza virus induced local and systemic inflammatory responses. Clin Immunol. 2020;217:108469.
   PubMed Web of Science ®Google Scholar
• Xiao XH, He SY. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24(6):3130–3142.
   PubMed Web of Science ®Google Scholar
• Tan L, Yuan J, Zhu W, et al. Interferon regulatory factor-1 suppresses DNA damage response and reverses chemotherapy resistance by downregulating the expression of RAD51 in gastric cancer. Am J Cancer Res. 2020;10(4):1255–1270.
   PubMed Web of Science ®Google Scholar
• Kim GW, Imam H, Khan M, et al. HBV -Induced increased N6 methyladenosine modification of PTEN RNA affects innate immunity and contributes to HCC. Hepatology. 2021;73(2):533–547.
   PubMed Web of Science ®Google Scholar
• Guo S, Zhu W, Yin Z, et al. Proanthocyanidins attenuate breast cancer-induced bone metastasis by inhibiting Irf-3/c-jun activation. Anticancer Drugs. 2019;30(10):998–1005.
   PubMed Web of Science ®Google Scholar
• Koelzer VH, Sokol L, Zahnd S, et al. Digital analysis and epigenetic regulation of the signature of rejection in colorectal cancer. Oncoimmunology. 2017;6(4):e1288330.
   PubMed Web of Science ®Google Scholar
• Okazaki S, Stintzing S, Sunakawa Y, et al. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Int J Cancer. 2017;141(6):1222–1230.
   PubMed Web of Science ®Google Scholar
• Jin J, Xiao Y, Hu H, et al. Proinflammatory TLR signalling is regulated by a TRAF2-dependent proteolysis mechanism in macrophages. Nat Commun. 2015;6:5930.
   PubMed Web of Science ®Google Scholar
• Malik S, Kakar N, Hasnain S, et al. Epidemiology of Van der Woude syndrome from mutational analyses in affected patients from Pakistan. Clin Genet. 2010;78(3):247–256.
   PubMed Web of Science ®Google Scholar
• Ingraham CR, Kinoshita A, Kondo S, et al. Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6). Nat Genet. 2006;38(11):1335–1340.
   PubMed Web of Science ®Google Scholar
• Edwards SK, Baron J, Moore CR, et al. Mutated in colorectal cancer (MCC) is a novel oncogene in B lymphocytes. J Hematol Oncol. 2014;7:56.
   PubMed Web of Science ®Google Scholar
• Li D, Cheng P, Wang J, et al. IRF6 is directly regulated by ZEB1 and ELF3, and predicts a favorable prognosis in gastric cancer. Front Oncol. 2019;9:220.
   PubMed Web of Science ®Google Scholar
• Xu HF, Huang T-J, Yang Q, et al. Candidate tumor suppressor gene IRF6 is involved in human breast cancer pathogenesis via modulating PI3K-regulatory subunit PIK3R2 expression. Cancer Manag Res. 2019;11:5557–5572.
   PubMed Web of Science ®Google Scholar
• Saleh SO, Hojaij FC, Itezeroti AM, et al. Level VI lymph nodes: an anatomic study of lymph nodes located between the recurrent laryngeal nerve and the right common carotid artery. Rev Col Bras Cir. 2018;45(6):e1972.
   PubMedGoogle Scholar
• Guo Z, Liang E, Li W, et al. Essential meiotic structure-specific endonuclease1 (EME1) promotes malignant features in gastric cancer cells via the Akt/GSK3B/CCND1 pathway. Bioengineered. 2021;12(2):9869–9884.
   PubMed Web of Science ®Google Scholar
• Wu MY, Liu L, Wang E-J, et al. PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation. Autophagy. 2021;17(5):1096–1111.
   PubMed Web of Science ®Google Scholar
• Wang S, Hu Q, Gao X, et al. Characteristics and effects on dental pulp cells of a polycaprolactone/submicron bioactive glass composite Scaffold. J Endod. 2016;42(7):1070–1075.
   PubMed Web of Science ®Google Scholar
• Gao X, Zheng X, Zhang Y, et al. Deficient or R273H and R248W mutations of p53 promote chemoresistance to 5-FU via TCF21/CD44 axis-mediated enhanced stemness in colorectal carcinoma. Front Cell Dev Biol. 2021;9:788331.
   PubMed Web of Science ®Google Scholar
• Lu J, Liu X, Zheng J, et al. Lin28A promotes IRF6-regulated aerobic glycolysis in glioma cells by stabilizing SNHG14. Cell Death Dis. 2020;11(6):447.
   PubMed Web of Science ®Google Scholar
• Rattanapornsompong K, Khattiya J, Phannasil P, et al. Impaired G2/M cell cycle arrest induces apoptosis in pyruvate carboxylase knockdown MDA-MB-231 cells. Biochem Biophys Rep. 2021;25:100903.
   PubMedGoogle Scholar
• Nambiyar K, Ahuja A, Bhardwaj M. A study of epithelial-mesenchymal transition immunohistochemical markers in primary oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021;132(6):680–686.
   PubMed Web of Science ®Google Scholar
• Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–226.
   PubMed Web of Science ®Google Scholar
• Chaffer CL, et al. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016;35(4):645–654.
   PubMed Web of Science ®Google Scholar
• Babaei G, Aziz SG, Jaghi NZZ. EMT, cancer stem cells and autophagy; The three main axes of metastasis. Biomed Pharmacother. 2021;133:110909.
   PubMed Web of Science ®Google Scholar
• Kim JH. Chemotherapy for colorectal cancer in the elderly. World J Gastroenterol. 2015;21(17):5158–5166.
   PubMed Web of Science ®Google Scholar
• McQuade RM, Stojanovska V, Bornstein JC, et al. Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem. 2017;24(15):1537–1557.
   PubMed Web of Science ®Google Scholar
• Modest DP, Pant S, Sartore-Bianchi A. Treatment sequencing in metastatic colorectal cancer. Eur J Cancer. 2019;109:70–83.
   PubMed Web of Science ®Google Scholar
• Wang D, Yang L, Yu W, et al. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling. J Immunother Cancer. 2019;7(1):215.
   PubMed Web of Science ®Google Scholar
• Fujita S, Kotake K. [Chemotherapy]. Nihon Rinsho. 2014;72(1):102–107.
   PubMedGoogle Scholar
• Lee JH, Yoon YM, Lee SH. GRP78 regulates apoptosis, cell survival and proliferation in 5-Fluorouracil-resistant SNUC5 colon cancer cells. Anticancer Res. 2017;37(9):4943–4951.
   PubMed Web of Science ®Google Scholar
• Sang J, Tang R, Yang M, et al. Metformin inhibited proliferation and metastasis of colorectal cancer and presented a synergistic effect on 5-FU. Biomed Res Int. 2020;2020:9312149.
   PubMed Web of Science ®Google Scholar
• Yan L, Yu -H-H, Liu Y-S, et al. Esculetin enhances the inhibitory effect of 5-Fluorouracil on the proliferation, migration and epithelial-mesenchymal transition of colorectal cancer. Cancer Biomark. 2019;24(2):231–240.
   PubMed Web of Science ®Google Scholar
• Woeste MR, Philips P, Egger ME, et al. Optimal perfusion chemotherapy: a prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer. J Surg Oncol. 2020;121(8):1298–1305.
   PubMed Web of Science ®Google Scholar
• Pérez-Escalante E, Cariño-Cortés R, Fernández-Martínez E, et al. Colorectal cancer: causes and evidence of chemopreventive treatments. Curr Pharm Biotechnol. 2018;19(14):1135–1155.
   PubMed Web of Science ®Google Scholar
• Li N, Chen M, Cao Y, et al. Bcl-2-associated athanogene 3(BAG3) is associated with tumor cell proliferation, migration, invasion and chemoresistance in colorectal cancer. BMC Cancer. 2018;18(1):793.
   PubMed Web of Science ®Google Scholar
• Mody K, Bekaii-Saab T. Clinical trials and progress in metastatic colon cancer. Surg Oncol Clin N Am. 2018;27(2):349–365.
   PubMed Web of Science ®Google Scholar
• Bailey CM, Hendrix MJ. IRF6 in development and disease: a mediator of quiescence and differentiation. Cell Cycle. 2008;7(13):1925–1930.
   PubMed Web of Science ®Google Scholar
• Ren Y, Dong J, He P, et al. miR-587 promotes cervical cancer by repressing interferon regulatory factor 6. J Gene Med. 2020;22(11):e3257.
   PubMed Web of Science ®Google Scholar
• Xu L, Huang T-J, Hu H, et al. The developmental transcription factor IRF6 attenuates ABCG2 gene expression and distinctively reverses stemness phenotype in nasopharyngeal carcinoma. Cancer Lett. 2018;431:230–243.
   PubMed Web of Science ®Google Scholar
• Slattery ML, Lundgreen A, Bondurant KL, et al. Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis. 2011;32(11):1660–1667.
   PubMed Web of Science ®Google Scholar
• Menon SS, Guruvayoorappan C, Sakthivel KM, et al. Ki-67 protein as a tumour proliferation marker. Clin Chim Acta. 2019;491:39–45.
   PubMed Web of Science ®Google Scholar
• Pathmanathan N, Balleine RL. Ki67 and proliferation in breast cancer. J Clin Pathol. 2013;66(6):512–516.
   PubMed Web of Science ®Google Scholar
• Diepenbruck M, Christofori G. Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe? Curr Opin Cell Biol. 2016;43:7–13.
   PubMed Web of Science ®Google Scholar
• Lu W, Kang Y. Epithelial-Mesenchymal plasticity in cancer progression and metastasis. Dev Cell. 2019;49(3):361–374.
   PubMed Web of Science ®Google Scholar
• Wong SHM, Fang CM, Chuah L-H, et al. E-cadherin: its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol. 2018;121:11–22.
   PubMed Web of Science ®Google Scholar
• Bure IV, Nemtsova MV, Zaletaev DV. Roles of E-cadherin and NONCODING RNAs in the epithelial-mesenchymal transition and progression in gastric cancer. Int J Mol Sci. 2019;20(12):2870.
   PubMed Web of Science ®Google Scholar
• Vassos N, Piso P. Metastatic colorectal cancer to the peritoneum: current treatment options. Curr Treat Options Oncol. 2018;19(10):49.
   PubMed Web of Science ®Google Scholar
• Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677–3683.
   PubMed Web of Science ®Google Scholar
• Zhang J, Miller Z, Musich PR, et al. DSTYK promotes metastasis and chemoresistance via EMT in colorectal cancer. Front Pharmacol. 2020;11:1250.
   PubMed Web of Science ®Google Scholar
• Glackin CA. Nanoparticle delivery of TWIST small interfering RNA and anticancer drugs: a therapeutic approach for combating cancer. Enzymes. 2018;44:83–101.
   PubMedGoogle Scholar